<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2024//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_240101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">24577041</PMID><DateCompleted><Year>2015</Year><Month>10</Month><Day>28</Day></DateCompleted><DateRevised><Year>2014</Year><Month>11</Month><Day>01</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1532-0987</ISSN><JournalIssue CitedMedium="Internet"><Volume>33</Volume><Issue>9</Issue><PubDate><Year>2014</Year><Month>Sep</Month></PubDate></JournalIssue><Title>The Pediatric infectious disease journal</Title><ISOAbbreviation>Pediatr Infect Dis J</ISOAbbreviation></Journal><ArticleTitle>Risk factors for critical disease and death from hand, foot and mouth disease.</ArticleTitle><Pagination><StartPage>966</StartPage><EndPage>970</EndPage><MedlinePgn>966-70</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1097/INF.0000000000000319</ELocationID><Abstract><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">There has been a high mortality and morbidity rate of critical and fatal patients from hand, foot and mouth disease (HFMD) in China in recent. Causes for development of critical and fatal disease remain unclear.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">We performed a case-control study to assess the association between use of drugs and development of critical disease and death from HFMD.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">We found that glucocorticoids treatment was associated with a greater incidence of severe HFMD, whereas andrographolides treatment was associated with a protective effect when they are used for treatment within 48 hours after onset or before being diagnosed as critical.</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">We recommend that glucocorticoids should not be used for mild HFMD and andrographolides should undergo clinical trials for treatment of enterovirus 71 infections.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>He</LastName><ForeName>Yilin</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>From the *Taizhou Center for Disease Control and Prevention, Jiangsu Province, Taizhou; &#x2020;Chinese Field Epidemiology Training Program, Chinese Center for Disease Control and Prevention, Beijing, China; &#x2021;U.S. Centers for Disease Control and Prevention, Atlanta, GA; and &#xa7;Chongqing Center for Disease Control and Prevention, Chongqing, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Yang</LastName><ForeName>Jianguo</ForeName><Initials>J</Initials></Author><Author ValidYN="Y"><LastName>Zeng</LastName><ForeName>Guang</ForeName><Initials>G</Initials></Author><Author ValidYN="Y"><LastName>Shen</LastName><ForeName>Tao</ForeName><Initials>T</Initials></Author><Author ValidYN="Y"><LastName>Fontaine</LastName><ForeName>Robert E</ForeName><Initials>RE</Initials></Author><Author ValidYN="Y"><LastName>Zhang</LastName><ForeName>Lijie</ForeName><Initials>L</Initials></Author><Author ValidYN="Y"><LastName>Shi</LastName><ForeName>Guoqing</ForeName><Initials>G</Initials></Author><Author ValidYN="Y"><LastName>Wang</LastName><ForeName>Yulin</ForeName><Initials>Y</Initials></Author><Author ValidYN="Y"><LastName>Li</LastName><ForeName>Qin</ForeName><Initials>Q</Initials></Author><Author ValidYN="Y"><LastName>Long</LastName><ForeName>Jiang</ForeName><Initials>J</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Pediatr Infect Dis J</MedlineTA><NlmUniqueID>8701858</NlmUniqueID><ISSNLinking>0891-3668</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000998">Antiviral Agents</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D004224">Diterpenes</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D005938">Glucocorticoids</NameOfSubstance></Chemical><Chemical><RegistryNumber>410105JHGR</RegistryNumber><NameOfSubstance UI="C030419">andrographolide</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000998" MajorTopicYN="N">Antiviral Agents</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016022" MajorTopicYN="N">Case-Control Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D002648" MajorTopicYN="N">Child</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D002675" MajorTopicYN="N">Child, Preschool</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D002681" MajorTopicYN="N" Type="Geographic">China</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016638" MajorTopicYN="N">Critical Illness</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004224" MajorTopicYN="N">Diterpenes</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005938" MajorTopicYN="N">Glucocorticoids</DescriptorName><QualifierName UI="Q000008" MajorTopicYN="N">administration &amp; dosage</QualifierName><QualifierName UI="Q000009" MajorTopicYN="Y">adverse effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006232" MajorTopicYN="N">Hand, Foot and Mouth Disease</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName><QualifierName UI="Q000401" MajorTopicYN="Y">mortality</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007223" MajorTopicYN="N">Infant</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012307" MajorTopicYN="N">Risk Factors</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012720" MajorTopicYN="N">Severity of Illness Index</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D013997" MajorTopicYN="N">Time Factors</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2014</Year><Month>3</Month><Day>1</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2014</Year><Month>3</Month><Day>1</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2015</Year><Month>10</Month><Day>29</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">24577041</ArticleId><ArticleId IdType="doi">10.1097/INF.0000000000000319</ArticleId></ArticleIdList></PubmedData></PubmedArticle></PubmedArticleSet>